Posted by admin on Jul 31, 2023 in |
Cutaneous aspergillosis is a rare locally invasive disease in immunocompromised patients caused primarily by Aspergillus species which induce primary infections through injured skin, burns, or locally infect via fungal contaminated adhesive dressings or intravenous catheter insertion, resulting in lesions to erythematous papules. About 80% of aspergillosis is caused by the ubiquitous and fastest-growing airborne fungi Aspergillus fumigatus leads to mortality in immunocompromised patients. Thioredoxin systems are one of the two main antioxidant systems in maintaining their cellular redox homeostasis essential for cell viability and occurring in all life forms. Thioredoxin reductase is one of the components of Thioredoxin system responsible for the normal growth of Aspergillus fumigatus. The present study deals with the in-silico analysis of binding efficiencies between phytochemicals from different medicinal plants with the target protein thioredoxin reductase of Aspergillus fumigatus using bioinformatics tools. The phytochemicals and target protein structure were retrieved from PubChem and PDB (ID:6BPY) databases, respectively. Qikprop module was used for ADME profiling of phytochemicals and the selected phytochemicals were subsequently docked with protein...
Read More
Posted by admin on Jul 31, 2023 in |
A series of novel thiazolidine-4-one-pyrazole hybrids (4a-4j) had been synthesized by Claisen-Schmidt condensation, Schiff’s base, and Cyclization mechanism. The newly synthesized target molecule structures were confirmed by IR, 1H NMR and Mass spectral data. The synthesized hybrids were screened for in-vitro anticancer and anthelmintic activities. The anticancer activity was assessed using MTT assay against MCF7 and SKVO3 cell lines and Doxorubicin as the reference standard. Anthelmintic activity of compounds was studied by using Albendazole as standard. Most synthesized hybrids (4j, 4h, 4b) showed good anticancer and anthelmintic activities. The molecular docking studies were performed using the Ligprep tool of the Schrodinger suite. This study revealed that novel thiazolidne-4-one-pyrazole hybrids (4a-4j) had good interaction with the active site of EGFR receptor. The compound 4j reported the highest dock score of -4.229 with a Glide binding energy of -52.98 Kcal/mol. The pyrazole hybrids’ dock score ranged from -4.229 to -2.19...
Read More
Posted by admin on Jul 31, 2023 in |
Staphylococcus aureusis a Gram-positive facultative pathogenic bacterium responsible for a wide range of infections ranging from skin to life-threatening infections. Antibiotic resistance of Staphylococcus aureus is an emerging global concern. Thus, developing viable antibiotics are in high demand. This study identified novel lead compounds from traditionally used medicinal plants via in-silico molecular docking and in-vitro antibacterial analysis. Thus, we have derived literature-evident phytocompounds from numerous traditional medicinal plants such as Boerhavia diffusa, Clerodendrum infortunatum, Sida rhombifolia, Tephrosia purpurea, Scoparia dulcis, Breynia retusa, Euphorbia heterophylla, Hemigraphis alternata, Hedyotis corymbose, Imperata cylindrica and their structures were retrieved from PubChem. Lipinski’s rule in ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) profiles were used to screen derived phytocompounds, followed by in-silico docking to the target protein. Clumping factor A (ClfA)-fibrinogen, a key virulence factor in S. aureus, was taken as a target protein. ClfA is a cell-wall-anchored protein that causes bacterial adherence to the blood plasma protein fibrinogen, which causes a variety of infections. Thus, an appealing strategy is to discover a novel lead compound with...
Read More
Posted by admin on Jul 31, 2023 in |
The primary goal of this study was to evaluate solid lipids as an alternative to polymers in the formulation of oral modified-release pastilles. Lipids have been used in pharmaceuticals since ancient times for a variety of purposes. They are used as polymer substitutes in the development of dosage forms. The solvent-free technique of pastillation uses lipids to formulate a modified-release oral dosage form explored in this research study. The melt solidification apparatus was developed at the laboratory scale to formulate hemispherical-shaped pastilles using solid lipid stearic acid; the apparatus was optimized by applying a 23-factorial design in Minitab. Three factors (X1 needle gage, X2 dropping height, and X3 base plate temperature) were considered and studied at 2-level.Optimized conditions were found to be ideal dropping height of 1 cm, a needle gauge of 20 G, and a cooling plate temperature of 4°C. Pastilles were characterized for drug content uniformity, 94 ± 1.64% to 98.8 ±1.03%; drug release of the F8 batch showed 99.98% ± 1.09 drug release at 12 hr;...
Read More
Posted by admin on Jul 31, 2023 in |
Moxifloxacin (MOX) is a second-line treatment for drug-susceptible and multidrug-resistant tuberculosis (MDR TB). MOX has poor patient compliance due to taste and odour concerns, particularly in the pediatric population. MOX taste-masked chewable tablets were developed by direct compression method using mannitol, aspartame, and sucralose as sweetening agents and lemon and peppermint flavor as flavoring agents. The lubricated granules were evaluated for flow properties, and compressed tablets were evaluated for hardness, friability, content uniformity, weight variation, DT and in-vitro drug release. FTIR, DSC, and XRD analysis were performed to detect any possible drug excipient compatibility issues and the nature of the drug molecule in the formulation. F6 formulation granules showed excellent flow properties, and batches manufactured with these granules showed physicochemical properties within acceptable limits. Complete drug release was observed within 8 minutes from the F6 formulation. FTIR and DSC studies demonstrated no drug excipient compatibility issues. According to XRD, the MOX in the final formulation was present in crystalline form. The dispersible MOX pills would be a superior alternative...
Read More
